June 25, 2014
2 min read
Save

ACIP recommends live attenuated influenza vaccine for healthy children

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The CDC’s Advisory Committee on Immunization Practices voted unanimously, 14-0, to recommend preferred use of live attenuated intranasal influenza vaccine for healthy children 2 to 8 years of age who have no contraindications or precautions.

Perspective from Mary C. Dundon, MD

This is the first time a recommendation has been made for a specific influenza vaccine.

In addition, revisions to recommendations regarding influenza vaccination for children with egg allergies and the pediatric dosing algorithm were discussed.

For the 2014-2015 influenza season, the ACIP recommended , the following:

  • All individuals aged older than 6 months should receive influenza vaccine. Influenza vaccination should not be delayed to procure a specific vaccine preparation if an appropriate one is already available;
  • When available, LAIV should be used for healthy children aged 2 to 8 years who have no contraindications or precautions. LAIV is not indicated for patients aged younger than 2 years or older than 49 years;
  • If LAIV is not immediately available, inactivated influenza vaccine should be used. Vaccination should not be delayed in order to procure LAIV.

Regarding dosage, the ACIP recommends children aged 6 months through 8 years receive two doses when receiving influenza vaccine for the first time. Further, physicians should consider the number of doses of pandemic 2009 H1N1 vaccine the patient has received. Children who received at least one dose of 2013 seasonal vaccine need only one dose in 2014.

Jeffrey Duchin, MD 

Jeffrey S. Duchin

Children with an egg allergy should not receive LAIV and should maintain a 30-minute wait period after receiving inactivated influenza vaccine in case of a negative reaction.

“The ACIP has formally acknowledged evidence for the superior effectiveness of LAIV in young children by incorporating a preference for LAIV use into their 2014-15 influenza vaccine recommendations. Both LAIV and inactivated injectable influenza vaccines are safe and effective vaccines. When LAIV is available, it should be used in healthy children 2 years through 8 years of age. Vaccination should not be postponed if LAIV is not available — inactivated influenza vaccine should be used,” ACIP member Jeffrey S. Duchin, MD, professor in medicine at the University of Washington, told Infectious Diseases in Children. — by Amanda Oldt